In summary, these data suggest CD4+ Treg can use the perforin and/or granzyme pathway in vitro and in vivo, and have the potential to target DCs, B cells, T-cells, NK cells, and tumor cells to control immune responses (Figure 1). This evidence concerns the gene PRF1 and neoplasm.